Molbio Diagnostics IPO: Date, Price ₹807, GMP & Review

Molbio Diagnostics IPO Details

Molbio Diagnostics IPO is a Mainboard IPO with an issue size of Rs. 939.70 Cr by Molbio Diagnostics Limited, comprising a combination of fresh issue of 0.25 crore shares (Rs. 200 Cr) and offer for sale of 0.92 crore shares (Rs. 739.70 Cr).

The Molbio Diagnostics IPO date of opening is 10 Aug 2026; its initial public offering will end on 12 Aug, IPO allotment on Aug 13, and refund initiation on Aug 14, 2026, and the listing date (expected) might be on Monday, Aug 17, 2026, on the BSE and NSE. 

The Molbio Diagnostics IPO price band is Rs. 768 to Rs. 807.

If you are also looking to apply in this IPO and are confused about whether you should proceed or not, then we have made an analysis in which we will be covering the company’s business, financials, industry trends, valuation, strengths and weaknesses, its current GMP indications, etc that can help you in taking a decision. Keep scrolling.

Molbio Diagnostics IPO- Company Analysis

is a multinational point-of-care (POC) molecular diagnostics business that conducts research, develops, produces, and markets quick diagnostic solutions for both infectious and non-communicable diseases. The business has created its exclusive "Truenat" platform, a battery-operated, portable PCR-based molecular diagnostics system that provides precise test results in an hour and is intended for environments with limited resources.

Through 43 diagnostic tests, Molbio provides molecular testing options for more than 30 diseases, including COVID-19, HIV, Hepatitis B and C, HPV, and tuberculosis (TB). Through its subsidiaries and strategic partnerships, the firm also offers radiography, digital pathology, and breast health screening products. Its robust internal R&D skills enable it to consistently grow its diagnostics product pipeline.

IPO Timetable (Tentative) 

Industry Growth and Health Industry Outlook

The diagnostics market was valued at ₹ 725.8 billion (USD 10.31 billion) in Fiscal 2021 and grew to ₹ 1,354.2 billion (USD 15.3 billion) in Fiscal 2026, at a CAGR of 13.3% for the said period and is projected to grow at a CAGR of 11.7% from Fiscal 2026 to 2031 and is estimated to reach a market value of ₹ 2,356.5 billion (USD 26.6 billion) in Fiscal 2031.

Click to open demat account and apply for the IPO.

The Objective of the Issue

• Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. ~ Rs. 125.12 Cr.

• Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit. ~ Rs. 80.81 Cr.
  
  

Promoters And Management of Molbio Diagnostics Ltd.

• Chandrasekhar Bhaskaran Nair

• Exxora Trading LLP

• Sangeetha Sriram

• Shiva Sriram

• Sowmya Sriram 

• Sriram Natarajan.

Annual Devices Sold (Truenat Platforms)

• Approximately 9,500 molecular diagnostic laboratories (CBNAAT + Truenat centres) in the public sector (including ~9,000 PHCs).

• Approximately 1,500 installations in the private sector.

• Potential private sector install base estimated at ~17,000.

• Truenat held the highest market share in installations under India’s NTEP (National Tuberculosis Elimination Programme) outside Designated Microscopy Centres from 2020–2022, with a 92% share of incremental installations since 2019.
  
  

Company Financials 

• The Total Assets (everything the company owns, such as land, machines, cash, and materials) have shown strong growth over the last three years, driven by business expansion, an increase in inventories, trade receivables, cash balances, property, plant & equipment, goodwill, and other intangible assets. As per the Restated Consolidated Financial Information, Total Assets stood at ₹21,484.24 million as at March 31, 2026 (up from ₹14,615.55 million as at March 31, 2025, and ₹12,210.56 million as at March 31, 2024).

• The Total Income (money earned from main business plus any other income) has grown steadily over the last three years on the back of higher sales of Truenat devices and test kits. Total Income stood at ₹14,551.70 million for the year ended March 31, 2026 (up from ₹10,279.36 million for the year ended March 31, 2025, and ₹8,406.59 million for the year ended March 31, 2024).

• The Profit After Tax (final profit left after paying all costs and taxes) has shown consistent improvement. Profit After Tax stood at ₹1,641.40 million for the year ended March 31, 2026 (up from ₹1,385.79 million for the year ended March 31, 2025, and ₹835.42 million for the year ended March 31, 2024).

• The EBITDA (operating profit before deducting interest, taxes, and asset wear-and-tear costs) has grown in line with the expansion in operations. EBITDA stood at ₹3,282.43 million for the year ended March 31, 2026 (up from ₹2,566.39 million for the year ended March 31, 2025, and ₹1,850.93 million for the year ended March 31, 2024).

• The Net Worth (total value belonging to the owners/shareholders of the company) has strengthened over the years. Net Worth stood at ₹11,446.76 million as at March 31, 2026 (up from ₹9,529.49 million as at March 31, 2025, and ₹8,079.39 million as at March 31, 2024).

• The Reserves (profits saved and kept inside the company for future use) stood at ₹11,580.60 million as at March 31, 2026 (up from ₹9,661.35 million as at March 31, 2025, and ₹8,211.27 million as at March 31, 2024). Within this, retained earnings alone were ₹9,226.59 million, ₹7,646.52 million and ₹6,202.92 million respectively.

• The Total Borrowings (total loans and debt taken by the company) increased significantly in Fiscal 2026 mainly due to fresh long-term borrowings. Total Borrowings stood at ₹4,126.38 million as at March 31, 2026 (comprising Non-current ₹2,124.06 million + Current ₹2,002.32 million), compared to ₹1,231.63 million as at March 31, 2025 and ₹1,745.77 million as at March 31, 2024.
  
  

Financials Snapshot

(Amount in Cr)

Cash Flows

• The Net Cash Flow from Operating Activities (cash generated from the company’s main day-to-day business after adjusting for working capital and taxes) stood at ₹95.70 million for the year ended March 31, 2024. It improved significantly to ₹2,871.03 million for the year ended March 31, 2025, and was ₹503.85 million for the year ended March 31, 2026. The strong cash generation in Fiscal 2025 was driven by higher operating profits and favourable working capital movements (especially reduction in trade receivables), while Fiscal 2026 saw lower net operating cash flow mainly due to an increase in trade receivables and other assets.

• Net Cash Flow from Investing Activities (cash used for buying/selling long-term assets like machinery, property, or investments) remained negative across all three years, reflecting continued capital expenditure and investments. It stood at ₹(450.10) million for the year ended March 31, 2024, ₹(1,226.53) million for the year ended March 31, 2025 (higher outflow due to investment in associates and PPE), and ₹(932.22) million for the year ended March 31, 2026.

• Net Cash Flow from Financing Activities (cash from loans, repayments, share issuance, and interest payments) stood at ₹(315.53) million for the year ended March 31, 2024 and ₹(261.47) million for the year ended March 31, 2025. It turned strongly positive at ₹2,760.66 million for the year ended March 31, 2026, primarily driven by proceeds from long-term borrowings of ₹2,247.70 million and net proceeds from short-term borrowings of ₹979.74 million.
  
  

Cash Flows Snapshot

(Amount in Mn)

Revenue Bifurcation

(Source: RHP)

Listed Peers of Molbio Diagnostics Ltd.

Test Kit Utilization

Valuation

• The Return on Equity (ROE), which measures the Company’s ability to generate profit from its shareholders’ equity, stood at 15.59% for the year ended March 31, 2026. It was 16.20% for the year ended March 31, 2025 and 13.20% for the year ended March 31, 2024.

• The Return on Capital Employed (ROCE), which measures the Company’s efficiency in generating returns from the capital employed in the business, stood at 17.55% for the year ended March 31, 2026. It was 20.98% for the year ended March 31, 2025 and 15.80% for the year ended March 31, 2024.

• The Debt to Equity Ratio, which indicates the proportion of debt used to finance the Company’s assets relative to equity, stood at 1.01 times as at March 31, 2026. It was 0.87 times as at March 31, 2025 and 0.72 times as at March 31, 2024.

• The Return on Net Worth (RoNW), which measures the Company’s ability to generate profit from its net worth, stood at 14.55% for the year ended March 31, 2026. It was 15.23% for the year ended March 31, 2025 and 12.62% for the year ended March 31, 2024.

• The Profit After Tax (PAT) Margin, which indicates the overall profitability of the Company as a percentage of total income, stood at 11.28% for the year ended March 31, 2026. It was 13.48% for the year ended March 31, 2025 and 9.94% for the year ended March 31, 2024.

• The EBITDA Margin, which indicates the operational profitability of the Company as a percentage of total income, stood at 22.56% for the year ended March 31, 2026. It was 24.97% for the year ended March 31, 2025 and 22.02% for the year ended March 31, 2024.
  
  

Valuation Snapshot

Is Valuation Expensive?

At the upper end of the price band of ₹807, Molbio Diagnostics is being valued at a Price-to-Earnings (P/E) multiple of approximately 54.63 times its Fiscal 2026 EPS of ₹14.77. For context, listed peers such as Poly Medicure (P/E 52.61x), Dr. Lal PathLabs (62.20x), Metropolis Healthcare (63.72x) and Vijaya Diagnostics (81.02x) currently trade in a broad range of roughly 52x to 81x.

Evaluation of P/E Ratio

Considering the period ended FY 2026 with an EPS of Rs. 14.77 from the last year, the resulting P/E ratio is 54.63x.

Explore the Xtranet Technologies IPO.

IPO's Strengths/ Bull Case

• WHO-approved TB molecular diagnostic method on a proprietary Truenat platform.

• Robust R&D skills backed by a large worldwide patent portfolio.

• Scalable business plan that generates recurrent income from diagnostic test kits.

• Global reach with a robust government and institutional clientele in more than 90 countries.

IPO's Weaknesses/ Risks for Investors/ Bear Case

• R&D & Product Approval Risk

• Uncertain Sales Demand

• Demand Forecasting & Inventory Risk.
  
  

Future Opportunities

• Rising Prevalence of Infectious Diseases- Increasing cases of infectious diseases like TB, hepatitis, etc. drive the demand for advanced molecular diagnostics.

• Technological Advancements- Innovations in PCR, next-generation sequencing & other molecular diagnostic technologies enhance accuracy and speed, boosting growth.

• Increasing Healthcare Awareness- Rising awareness of the benefits of molecular diagnostics among healthcare professionals and the general population is driving the demand.
  
  

Molbio Diagnostics IPO GMP

Molbio Diagnostics IPO GMP today has not started yet as of 05 August 2026, while writing this information. 

Anchor Investors

Details of anchor participation (if any) would be available in filings; pre-IPO investors include entities like Anchorage Capital and Baring PE.

Subscription Status (Live)

Subscription data will be available during/after the issue period on BSE/NSE websites. Check official sources for real-time updates.

Molbio Diagnostics IPO Lesser Known Facts

• Exxora Trading LLP, which holds 4,64,87,600 equity shares at an average cost of just ₹0.20 per share, has a current market value of approximately ₹3,751.55 crore. Against a total acquisition cost of only ₹0.93 crore, this translates into a notional profit of around ₹3,750.62 crore, or ₹806.80 per share.

• Dr. Chandrasekhar Bhaskaran Nair (who holds shares jointly with Anita Angela Chandrasekhar) owns 61,09,850 equity shares acquired at an average cost of ₹6.90 per share. At the current price of ₹807, the market value of these shares is about ₹493.06 crore. After accounting for the acquisition cost of ₹4.22 crore, the notional profit works out to approximately ₹488.85 crore, or ₹800.10 per share.

• Molbio became the first Indian company to receive the Class C IVDR (EU 2017/746) Technical Documentation Assessment Certificate for its Truenat CT/NG test.

• Truenat Nipah virus test chip was the first in India to receive emergency use authorisation from the Drug Controller General of India (DCGI).
  
  

Who Should Avoid this IPO? / Who Should Apply?

Every investor has different risk appetite, financial goals, and analysis methods. The blog suggests reviewing the full RHP, latest GMP, subscription trends, etc. Allotment is not guaranteed, and market conditions on listing day also matter.

Molbio Diagnostics IPO Summary

IPO Lot Details

Molbio Diagnostics IPO Allotment Status

To check the Molbio Diagnostics IPO Allotment Status, visit the official Registrar’s website or the BSE website. Below are the website links for you.

Using BSE Website - ​BSE IPO allotment status

IPO Lead Managers

• Kotak Mahindra Capital Co. Ltd.
  
  

Dividend Policy

The company has not paid a Dividend during the last three FYs.

Should You Apply for Molbio Diagnostics IPO?

Investors are advised to carefully read the full Red Herring Prospectus, evaluate the latest Grey Market Premium (if any), monitor subscription trends during the issue period, and consider their own financial goals and risk tolerance. Consulting a SEBI-registered investment advisor is recommended before making any decision.

Conclusion

Molbio Diagnostics shows strong revenue growth, improving profitability, and a scalable diagnostics business supported by its proprietary Truenat platform. However, the IPO appears fairly valued to expensive at a P/E of around 54.63x, while rising debt and weaker FY26 operating cash flow remain key concerns.

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to provide all the required details about the company you should know before applying for the IPO.

You must consult your financial advisor before making any financial decisions.

To Apply for the IPO, Click Here.

To read the Prospectus of the company, click here to download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.